М. I. Shkolnik

1.6k total citations · 1 hit paper
27 papers, 455 citations indexed

About

М. I. Shkolnik is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, М. I. Shkolnik has authored 27 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in М. I. Shkolnik's work include Renal cell carcinoma treatment (7 papers), Prostate Cancer Treatment and Research (6 papers) and Bladder and Urothelial Cancer Treatments (4 papers). М. I. Shkolnik is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Prostate Cancer Treatment and Research (6 papers) and Bladder and Urothelial Cancer Treatments (4 papers). М. I. Shkolnik collaborates with scholars based in Russia, United States and Taiwan. М. I. Shkolnik's co-authors include B. Yа. Alekseev, Simon J. Crabb, Kenneth J. Pienta, Jean-Pascal Machiels, Thomas A. Puchalski, Dirk Schrijvers, Johann S. de Bono, Chris H. Takimoto, Susan Li and Shobha Seetharam and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

М. I. Shkolnik

15 papers receiving 448 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

2012 336 citations Kenneth J. Pienta, Jean-Pascal Machiels et al. Investigational New Drugs profile →

Peers

Countries citing papers authored by М. I. Shkolnik

Since Specialization

Citations

This map shows the geographic impact of М. I. Shkolnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by М. I. Shkolnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites М. I. Shkolnik more than expected).

Fields of papers citing papers by М. I. Shkolnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by М. I. Shkolnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by М. I. Shkolnik. The network helps show where М. I. Shkolnik may publish in the future.

Co-authorship network of co-authors of М. I. Shkolnik

This figure shows the co-authorship network connecting the top 25 collaborators of М. I. Shkolnik. A scholar is included among the top collaborators of М. I. Shkolnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with М. I. Shkolnik. М. I. Shkolnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative analysis of the results of surgical treatment of kidney cancer complicated by tumor thrombosis of renal vein and inferior vena cava of level I–II 2025 ·Perm Medical Journal ·(unknown), (unknown), М. I. Shkolnik, (unknown)	0
2	Migration of Hem-o-Lok clips into the bladder after radical prostatectomy – own experience 2024 ·Perm Medical Journal ·(unknown), (unknown), М. I. Shkolnik, (unknown), (unknown), (unknown)	0
3	Optimization of staging algorithm for newly detected prostate cancer by using PET/CT with <sup>68</sup>Ga-PSMA: a retrospective study 2023 ·Diagnostic radiology and radiotherapy ·(unknown), (unknown), (unknown), М. I. Shkolnik, (unknown), (unknown), (unknown), (unknown)	0
4	PET/CT Imaging of Prostate Cancer. Modern Versions of Radiopharmaceuticals 2021 ·(unknown), (unknown), (unknown), М. I. Shkolnik, (unknown), (unknown), (unknown)	0
5	THE TREATENT OF PRIMARY MULTIPLE CANCER IN A PATIENT WITH A KIDNEY GRAFT. CLINICAL INCIDENCE 2020 ·Voprosy Onkologii ·(unknown), Artur Belov, (unknown), (unknown), (unknown), М. I. Shkolnik, (unknown), (unknown)	0
6	EXPERIMENTAL MODELS OF RADIATION-INDUCED CYSTITIS IN LABORATORY ANIMALS (LITERATURE REVIEW) 2019 ·Voprosy Onkologii ·(unknown), (unknown), (unknown), (unknown), М. I. Shkolnik, (unknown)	0
7	Efficacy of incomplete metastasectomy in combination with targeted therapy in metastatic kidney cancer patients 2019 ·SHILAP Revista de lepidopterología ·(unknown), Р. В. Орлова, М. I. Shkolnik, Petr Karlov, Э. Э. Топузов	1
8	FEATURES OF DIAGNOSIS AND TREATMENT OF A PATIENT WITH CANCER OF THE RIGHT KIDNEY IN COMBINATION WITH DISSEMINATED ABDOMINAL AND RETROPERITONEAL SPLENOSIS 2018 ·Voprosy Onkologii ·(unknown), М. I. Shkolnik, (unknown), (unknown), (unknown)	2
9	MODERN APPROACHES IN TREATMENT FOR LOCALLY ADVANCED PROSTATE CANCER 2018 ·Voprosy Onkologii ·М. I. Shkolnik, (unknown), (unknown), (unknown), (unknown)	0
10	Functional and early oncological results in 2D vs 3D laparoscopic prostatectomy 2018 ·Urology reports (St - Petersburg) ·(unknown), М. I. Shkolnik, (unknown), (unknown), (unknown), (unknown), (unknown)	1
11	Salvage lymphadenectomy in patients with lymphogenic prostate cancer progression after radical treatment: results of a multicenter study 2016 ·Cancer Urology ·B. Yа. Alekseev, K. М. Nyushko, (unknown), А. К. Носов, (unknown), (unknown), (unknown), (unknown), М. I. Shkolnik, (unknown), (unknown), А. Д. Каприн	2
12	Using 320-slice perfusion computed tomography in visuali zation of prostate cancer 2016 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), М. I. Shkolnik, (unknown), (unknown)	0
13	Efficacy of incomplete metastasectomy with targeted therapy in patients with metastatic renal cell carcinoma. 2016 ·Journal of Clinical Oncology ·Р. В. Орлова, (unknown), Petr Karlov, М. I. Shkolnik	0
14	Evaluation of the efficiency of combination palliative treatment in patients with metastatic clear-cell renal cell carcinoma 2015 ·SHILAP Revista de lepidopterología ·(unknown), Р. В. Орлова, М. I. Shkolnik, Petr Karlov	0
15	The frequency of radiation damage in patients with prostate cancer who received the combined treatment after closure of cystostomy 2015 ·SHILAP Revista de lepidopterología ·(unknown), М. I. Shkolnik, (unknown), (unknown)	0
16	RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma 2015 ·Annals of Oncology ·Alain Ravaud, Carlos H. Barrios, B. Yа. Alekseev, (unknown), Sanjiv S. Agarwala, Şuayib Yalçın, (unknown), Laslo Roman, М. I. Shkolnik, Oezlem Anak, (unknown), Diana Pelov, (unknown), Bohuslav Melichar	60
17	DIAGNOSIS OF RECURRENT BLADDER CANCER BY FLUORESCENCE IN SITU HYBRIDIZATION ASSAY ON URINE SEDIMENT CELLS 2014 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), М. I. Shkolnik, (unknown), (unknown)	1
18	Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results. 2013 ·Journal of Clinical Oncology ·Alain Ravaud, Carlos H. Barrios, B. Yа. Alekseev, Miah Hiang Tay, Sanjiv S. Agarwala, Şuayib Yalçın, Chia‐Chi Lin, М. I. Shkolnik, В. Б. Матвеев, Özlem Anak, Sven Gogov, Diana Pelov, (unknown), (unknown), Bohuslav Melichar	7
19	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer breakdown → 2012 ·Investigational New Drugs ·Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, B. Yа. Alekseev, М. I. Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, Chris H. Takimoto, Yusri Elsayed, Fitzroy W. Dawkins, Johann S. de Bono	336
20	Методы термодеструкции в лечении почечно-клеточного рака 2006 ·(unknown), (unknown), М. I. Shkolnik, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact